NCT01527149View on ClinicalTrials.gov

Ofatumumab in Combination With Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine Sulfate, and Dexamethasone Alternating With Ofatumumab in Combination With Cytarabine and Methotrexate in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma

PHASE2CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

December 6, 2011

Primary Completion Date

April 26, 2018

Study Completion Date

January 11, 2024

Conditions
Stage I Mantle Cell LymphomaStage II Contiguous Mantle Cell LymphomaStage II Non-Contiguous Mantle Cell LymphomaStage III Mantle Cell LymphomaStage IV Mantle Cell Lymphoma
Interventions
PROCEDURE

Autologous Hematopoietic Stem Cell Transplantation

Undergo autologous HDC-ASCT

DRUG

Cyclophosphamide

Given IV

DRUG

Cytarabine

Given IV

DRUG

Dexamethasone

Given IV or PO

DRUG

Doxorubicin Hydrochloride

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Methotrexate

Given IV

BIOLOGICAL

Ofatumumab

Given IV

DRUG

Vincristine Sulfate

Given IV

Trial Locations (2)

14263

Roswell Park Cancer Institute, Buffalo

37232

Vanderbilt University/Ingram Cancer Center, Nashville

All Listed Sponsors
collaborator

National Comprehensive Cancer Network

NETWORK

lead

Roswell Park Cancer Institute

OTHER

NCT01527149 - Ofatumumab in Combination With Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine Sulfate, and Dexamethasone Alternating With Ofatumumab in Combination With Cytarabine and Methotrexate in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma | Biotech Hunter | Biotech Hunter